Factors affecting the life expectancy in malignant pleural mesothelioma: Our 10 years of studies and experience

• Published in: Medicine (Baltimore) Vol. 101; no. 39; p. e30711
• Main Authors: Cimen, Filiz, Agackiran, Yetkin, Düzgün, Sevim, Aloglu, Melike, Senturk, Aysegül, Atikcan, Sükran
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 30-09-2022
• Subjects: Female; Fluorodeoxyglucose F18; Humans; Life Expectancy; Lung Neoplasms - pathology; Male; Mesothelioma - diagnosis; Mesothelioma, Malignant; Observational Study; Pleural Diseases; Pleural Neoplasms - pathology; Positron Emission Tomography Computed Tomography - methods; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed
• ISSN: 1536-5964; 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000030711

Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis. In our study, we aimed to investigate the specific clinical, laboratory, and radiological features of the tumor and the prognostic effect of SUVmax (maximum standardized uptake values) according to PET/CT (positron emission tomography). Demographic, therapeutic, clinical, and survival information of patients diagnosed with histologically-validated pleural mesothelioma in our hospital between January 2010 to December 2019 will be retrospectively scanned from the hospital records. A total of 116 patients, 61 men (52.6%), and 55 women (47.4%), were analyzed. Thirty five patients (30.2%) were over the age of 65. Percentage of patients over 65 years of age, neutrophil count, and PET SUV Max values, asbestos exposure and pleural thickening rate were significantly higher in the deceased patients’ group than in the living patients’ group (P = .042, P = .039, P = .002, P = .004, P = .037). T stage (tumor stage), N stage (lymph nodes stage), metastasis stage, and Grade distribution were significantly higher in the deceased patients’ group than in the living patients’ group (P < .000, P < .000, P = .003, P < .000). The rates of chemotherapy and surgical treatment, right lung location, and epithelioid pathology were significantly lower in the deceased patients’ group compared to the living patients’ group (P = .016, P = .030, P = .018, P = .008). The mean follow-up time was 13 months. Key determinants of survival in MPM include age, male gender, neutrophil increase, pleural thickening, high PET SUV max values, stage, histological type, asbestos exposure, and treatment regimen.